We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Puma (PBYI) This Earnings Season?
Read MoreHide Full Article
Puma Biotechnology, Inc. (PBYI - Free Report) is scheduled to report fourth-quarter 2017 results on Mar 1 after market close.
The company’s earnings track record has been impressive so far with an average positive surprise of 41.48% in the last four quarters.
Puma’s shares have significantly outperformed the industry in a year’s time. While the stock has skyrocketed 82.7%, the industry has recorded a decrease of 3.3%.
Last quarter, Puma delivered a positive surprise of 50.55%. Let’s see, how things are shaping up for this announcement.
Factors at Play
Puma Biotechnology’s only marketed product, Nerlynx (neratinib), was launched in the United States for the treatment of HER2-positive breast cancer in August 2017. Though the company generated nominal sales from the drug in the third quarter, it is expected to generate some encouraging revenues in the to-be-reported quarter, given the company’s aggressive commercialization efforts for the same.
Notably, last November, Puma entered into an exclusive licensing agreement with Specialised Therapeutics Asia, a Singapore-based biotechnology company to commercialize Nerlynx in Australia, New Zealand and Southeast Asia.
The drug is also under review in the EU for the same indication. However, this month, the company announced that the Committee for Medicinal Products for Human Use has adopted a negative opinion, recommending the refusal of the Marketing Authorization Application for Nerlynx in the EU. Puma plans to submit a request for re-examining the opinion by the regulatory agency soon.
Several additional studies on neratinib targeting different types of breast cancer patient populations and in earlier-line settings are underway. Also, several phase II combination trials evaluating Nerlynx for the treatment of breast cancer are on.
Apart from the HER2-positive breast cancer indication, the company believes that neratinib holds potential for treating several other cancers including NSCLC and other tumor types that over-express or have a mutation in HER2.
We expect an update on some of these studies on fourth-quarter conference call.
What Our Model Indicates
Our proven model does not conclusively show that Puma is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a bullish Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Zacks ESP: Puma has an Earnings ESP of 0.00% as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of $1.98. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Puma has a Zacks Rank #3, which increases the predictive power of ESP. However, a company’s 0.00% Earnings ESP makes surprise prediction difficult.
We caution against Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Atara Biotherapeutics, Inc. (ATRA - Free Report) is expected to announce fourth-quarter results on Mar 8. The company has an Earnings ESP of +7.42% and a Zacks Rank #3.
Aptose Biosciences, Inc. (APTO - Free Report) is expected to release fourth-quarter financial numbers on Mar 27. The company has an Earnings ESP of +20.00% and is a Zacks #3 Ranked palyer.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
What's in the Cards for Puma (PBYI) This Earnings Season?
Puma Biotechnology, Inc. (PBYI - Free Report) is scheduled to report fourth-quarter 2017 results on Mar 1 after market close.
The company’s earnings track record has been impressive so far with an average positive surprise of 41.48% in the last four quarters.
Puma’s shares have significantly outperformed the industry in a year’s time. While the stock has skyrocketed 82.7%, the industry has recorded a decrease of 3.3%.
Last quarter, Puma delivered a positive surprise of 50.55%. Let’s see, how things are shaping up for this announcement.
Factors at Play
Puma Biotechnology’s only marketed product, Nerlynx (neratinib), was launched in the United States for the treatment of HER2-positive breast cancer in August 2017. Though the company generated nominal sales from the drug in the third quarter, it is expected to generate some encouraging revenues in the to-be-reported quarter, given the company’s aggressive commercialization efforts for the same.
Notably, last November, Puma entered into an exclusive licensing agreement with Specialised Therapeutics Asia, a Singapore-based biotechnology company to commercialize Nerlynx in Australia, New Zealand and Southeast Asia.
The drug is also under review in the EU for the same indication. However, this month, the company announced that the Committee for Medicinal Products for Human Use has adopted a negative opinion, recommending the refusal of the Marketing Authorization Application for Nerlynx in the EU. Puma plans to submit a request for re-examining the opinion by the regulatory agency soon.
Several additional studies on neratinib targeting different types of breast cancer patient populations and in earlier-line settings are underway. Also, several phase II combination trials evaluating Nerlynx for the treatment of breast cancer are on.
Apart from the HER2-positive breast cancer indication, the company believes that neratinib holds potential for treating several other cancers including NSCLC and other tumor types that over-express or have a mutation in HER2.
We expect an update on some of these studies on fourth-quarter conference call.
What Our Model Indicates
Our proven model does not conclusively show that Puma is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a bullish Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Zacks ESP: Puma has an Earnings ESP of 0.00% as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of $1.98. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Puma has a Zacks Rank #3, which increases the predictive power of ESP. However, a company’s 0.00% Earnings ESP makes surprise prediction difficult.
We caution against Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Puma Biotechnology, Inc. Price and EPS Surprise
Puma Biotechnology, Inc. Price and EPS Surprise | Puma Biotechnology, Inc. Quote
Stocks That Warrant a Look
Here are some health care stocks with the right combination of elements to beat on earnings this time around:
Gemphire Therapeutics is expected to report fourth-quarter 2017 earnings on Mar 21. The company has an Earnings ESP of +8.01% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Atara Biotherapeutics, Inc. (ATRA - Free Report) is expected to announce fourth-quarter results on Mar 8. The company has an Earnings ESP of +7.42% and a Zacks Rank #3.
Aptose Biosciences, Inc. (APTO - Free Report) is expected to release fourth-quarter financial numbers on Mar 27. The company has an Earnings ESP of +20.00% and is a Zacks #3 Ranked palyer.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>